295 related articles for article (PubMed ID: 36661476)
1. Frontiers in mass spectrometry-based clinical proteomics for cancer diagnosis and treatment.
Haga Y; Minegishi Y; Ueda K
Cancer Sci; 2023 May; 114(5):1783-1791. PubMed ID: 36661476
[TBL] [Abstract][Full Text] [Related]
2. Cancer proteogenomics: current impact and future prospects.
Mani DR; Krug K; Zhang B; Satpathy S; Clauser KR; Ding L; Ellis M; Gillette MA; Carr SA
Nat Rev Cancer; 2022 May; 22(5):298-313. PubMed ID: 35236940
[TBL] [Abstract][Full Text] [Related]
3. Proteogenomic interrogation of cancer cell lines: an overview of the field.
Tsang O; Wong JWH
Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
[No Abstract] [Full Text] [Related]
4. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research.
Macklin A; Khan S; Kislinger T
Clin Proteomics; 2020; 17():17. PubMed ID: 32489335
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
Murray HC; Dun MD; Verrills NM
Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine.
Ang MY; Low TY; Lee PY; Wan Mohamad Nazarie WF; Guryev V; Jamal R
Clin Chim Acta; 2019 Nov; 498():38-46. PubMed ID: 31421119
[TBL] [Abstract][Full Text] [Related]
7. Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.
Manes NP; Nita-Lazar A
J Proteomics; 2018 Oct; 189():75-90. PubMed ID: 29452276
[TBL] [Abstract][Full Text] [Related]
8. Proteogenomics from a bioinformatics angle: A growing field.
Menschaert G; Fenyö D
Mass Spectrom Rev; 2017 Sep; 36(5):584-599. PubMed ID: 26670565
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomics for understanding oncology: recent advances and future prospects.
Subbannayya Y; Pinto SM; Gowda H; Prasad TS
Expert Rev Proteomics; 2016; 13(3):297-308. PubMed ID: 26697917
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomics: Key Driver for Clinical Discovery and Personalized Medicine.
Barbieri R; Guryev V; Brandsma CA; Suits F; Bischoff R; Horvatovich P
Adv Exp Med Biol; 2016; 926():21-47. PubMed ID: 27686804
[TBL] [Abstract][Full Text] [Related]
11. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
[TBL] [Abstract][Full Text] [Related]
12. Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics.
Rodland KD; Piehowski P; Smith RD
Cancer J; 2018; 24(3):121-125. PubMed ID: 29794536
[TBL] [Abstract][Full Text] [Related]
13. A proteogenomics data-driven knowledge base of human cancer.
Liao Y; Savage SR; Dou Y; Shi Z; Yi X; Jiang W; Lei JT; Zhang B
Cell Syst; 2023 Sep; 14(9):777-787.e5. PubMed ID: 37619559
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic examination of esophageal squamous cell carcinoma (ESCC): new lines of inquiry.
Dagamajalu S; Vijayakumar M; Shetty R; Rex DAB; Narayana Kotimoole C; Prasad TSK
Expert Rev Proteomics; 2020 Sep; 17(9):649-662. PubMed ID: 33151123
[No Abstract] [Full Text] [Related]
15. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.
Rodriguez H; Zenklusen JC; Staudt LM; Doroshow JH; Lowy DR
Cell; 2021 Apr; 184(7):1661-1670. PubMed ID: 33798439
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas.
Li J; Zhan X
Biochim Biophys Acta Proteins Proteom; 2021 Mar; 1869(3):140584. PubMed ID: 33321259
[TBL] [Abstract][Full Text] [Related]
17. Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines.
Alfaro JA; Ignatchenko A; Ignatchenko V; Sinha A; Boutros PC; Kislinger T
Genome Med; 2017 Jul; 9(1):62. PubMed ID: 28716134
[TBL] [Abstract][Full Text] [Related]
18. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
19. Proteomic and genomic profiling of pancreatic cancer.
Ansari D; Torén W; Zhou Q; Hu D; Andersson R
Cell Biol Toxicol; 2019 Aug; 35(4):333-343. PubMed ID: 30771135
[TBL] [Abstract][Full Text] [Related]
20. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.
Hernandez-Valladares M; Vaudel M; Selheim F; Berven F; Bruserud Ø
Expert Rev Proteomics; 2017 Aug; 14(8):649-663. PubMed ID: 28693350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
